short T1/2 dual orexin 1/2 receptor antagonist
in clinical dev. for insomnia (Ph. II)
from ligand-based drug design
Bioorg. Med. Chem., Apr. 11, 2020
Taisho Pharmaceutical Co., Saitama, JP
ORN0829
1 min read
ORN0829 is a dual inhibitor of orexins 1 and 2, designed to have a relatively short half life in humans for application in insomnia (to reduce side effects after waking up). Chemically it has an interesting chiral 1,3-oxazinane amide motif, which is resolved in their med. chem. route through an enzymatic resolution.
Search By Structure
- tucatinib
- S6821
- MRTX849
- BAY1161909
- ORN0829
- BMS-986251
- GSK2818713
- CPI-1612
- “Compound 19”
- AZD4205
- QPX7728
- “Compound 9”
- “Compound (P)-14″
- FT385
Molecules of the Month
2023
2022
2021
2020